Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage 0 bladder cancer
Trial Type:  Treatment
Results 1-21 of 21 for your search:
Start Over
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.7, NCI-2015-01830, BOND 2 version 3.4, NCT02365818
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB4-845-02-IIIA, NCI-2015-01369, NCT02449239
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SPI-EOQ-13-305, NCI-2016-00340, NCT02563561
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: rAd-IFN-CS-003, NCI-2016-01157, NCT02773849
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: BC001, NCI-2015-01102, NCT02009332
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: WO29635, NCI-2016-01018, NCT02792192
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Dovitinib Lactate in Treating Patients With Refractory or Stage 0-I Bladder Cancer With FGFR3 Mutations or Overexpression
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU12-157, NCI-2013-00610, CTKI258AUS17T, 1211009949, NCT01732107
BCG Solution in Treating Patients with Non-muscle Invasive Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-174, NCI-2014-02528, NCT02281383
Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-057, NCI-2016-00312, 2014-004026-17, NCT02625961
Robotic or Open Radical Cystectomy in Treating Patients with Bladder Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 4B-15-4, NCI-2016-00080, HS-15-00731, NCT02699853
Atezolizumab in Treating Patients with Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1605, NCI-2016-01104, NCT02844816
Cabazitaxel, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with BCG solution-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM8506, NCI-2015-00757, NCT02202772
Pembrolizumab and BCG Solution in Treating Patients with Recurrent Non-Muscle-Invasive Bladder Cancer
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NU 15U06, NCI-2016-00664, STU00202754, NCT02808143
Ethacrynic Acid in Treating Patients with Non-muscle Invasive Bladder Cancer Undergoing Transurethral Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-IIT-Ethacrynic-Acid, NCI-2016-01355, NCT02852564
Intracorporeal or Extracorporeal Urinary Diversion during Robotic Assisted Radical Cystectomy in Reducing Complications in Patients with Bladder Cancer
Status: Not yet active
Phase: No phase specified
Type: Supportive care, Treatment
Age: Not specified
Trial IDs: CASE 7814, NCI-2014-01530, NCT02252393
BGJ398 in Treating Patients with Non-Muscle-Invasive Urothelial Cancer of the Bladder
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-090, NCI-2016-00119, NCT02657486
Observation or Immediate Surgery in Reducing Complications in Patients with Low Risk Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 50 and over
Trial IDs: VICC URO 15139, NCI-2016-00677, NCT02700724
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Sirolimus and BCG in Treating Patients with Non-muscle Invasive Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 16-162H, NCI-2016-01361, CTMS 16-0011, HSC20160162H, NCT02753309
Start Over